Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EBITDA: 2013-2024

Historic EBITDA for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to -$270.3 million.

  • Viridian Therapeutics, Inc.\DE's EBITDA rose 54.39% to -$34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 18.14%. This contributed to the annual value of -$270.3 million for FY2024, which is 14.05% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported EBITDA of -$270.3 million as of FY2024, which was down 14.05% from -$237.0 million recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's EBITDA ranged from a high of -$79.6 million in FY2021 and a low of -$270.3 million during FY2024.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's EBITDA had a median value of -$237.0 million in 2023 and averaged -$212.5 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's EBITDA plummeted by 164.44% in 2020, and later rose by 28.14% in 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's EBITDA (Yearly) stood at -$110.7 million in 2020, then increased by 28.14% to -$79.6 million in 2021, then slumped by 63.53% to -$130.1 million in 2022, then slumped by 82.16% to -$237.0 million in 2023, then fell by 14.05% to -$270.3 million in 2024.